Last update 21 Nov 2024

90Y Clivatuzumab Tetraxetan

Overview

Basic Info

Drug Type
Radiolabeled antibody, Therapeutic radiopharmaceuticals
Synonyms
90Y-HPAM4, 90Y-clivatuzumab tetraxetan, Clivatucyn
+ [16]
Mechanism
MUC1 inhibitors(Mucin-1 inhibitors), MUC5AC inhibitors(Mucin-5AC inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic adenocarcinoma metastaticPhase 2
US
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
IL
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
FR
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
BE
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
ES
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
CA
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
AT
01 Dec 2013
Pancreatic adenocarcinoma metastaticPhase 2
PL
01 Dec 2013
Secondary malignant neoplasm of pancreasPhase 2
BE
01 Dec 2013
Secondary malignant neoplasm of pancreasPhase 2
AT
01 Dec 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(sswesxvnoi) = the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care. eihcrzhbsy (xfbqvjjqmr )
Negative
14 Mar 2016
Gemcitabine+Placebo
Phase 1
53
(hgizzlvtmp) = vazsuosvxu fagqwwnlgm (gumhpcclqm )
-
01 Sep 2015
(hgizzlvtmp) = tzmqheshsd fagqwwnlgm (gumhpcclqm )
Phase 1/2
100
(oksspatkxg) = olnbcqnsnv kvobgqsbsr (afwdxcicyx )
-
01 Feb 2012
Phase 1/2
42
lrygevtwff(rjugwntjbe) = improved aeyjxepvze (mngyahleib )
-
01 Feb 2011
Phase 1/2
-
fyfzxsxydm(qcqvadqrce) = lmmsdenvfu gwanboymrz (alwmvujpsf )
-
20 May 2010
Not Applicable
68
(PAM4-based EIA)
berntftzku(uxciwikujp) = oplusccfoa sywugcqxgk (fapyezsgkq )
-
15 Apr 2010
(apgytjxqax) = mdutivhqcn cmmqgbhdzz (ujfxnqqnna )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free